Taira Maekawa

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. ncbi The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku 606 8507, Japan
    Int J Clin Oncol 12:327-40. 2007
  2. ncbi INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Blood 109:306-14. 2007
  3. ncbi The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara Shogoin Sakyo-ku, Kyoto 606-8507, Japan
    Leuk Res 29:451-7. 2005
  4. ncbi Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    Mol Cancer Ther 7:2904-12. 2008
  5. ncbi Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Br J Haematol 130:558-60. 2005
  6. ncbi A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 294:245-53. 2010
  7. ncbi Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor
    Rina Nagao
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 312:91-100. 2011
  8. ncbi Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan
    Oncol Res 15:1-9. 2005
  9. ncbi Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Hematol 79:37-43. 2004
  10. ncbi Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Blood 116:2089-95. 2010

Detail Information

Publications70

  1. ncbi The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku 606 8507, Japan
    Int J Clin Oncol 12:327-40. 2007
    ....
  2. ncbi INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Blood 109:306-14. 2007
    ..Furthermore, cyclosporine A, a P-glycoprotein inhibitor, augmented the in vivo activity of INNO-406 against CNS Ph+ leukemia. These findings indicate that INNO-406 is a promising agent for the treatment of CNS Ph+ leukemia...
  3. ncbi The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara Shogoin Sakyo-ku, Kyoto 606-8507, Japan
    Leuk Res 29:451-7. 2005
    ..Importantly, YM529 prolonged the survival of NOD/SCID mice engrafted with human primary leukemic cells. These findings indicate that the YM529 may become a novel molecular therapeutic class for treatment of leukemias...
  4. ncbi Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    Mol Cancer Ther 7:2904-12. 2008
    ..This study shows the efficacy of i.v. administration of PLK-1 siRNA/atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer...
  5. ncbi Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth
    Hidekazu Segawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Br J Haematol 130:558-60. 2005
    ..These findings suggest that the combination of ZOL and imatinib accelerate the eradication of Ph+ clone, resulting in better prognosis of Ph+ leukaemia patients who have not yet acquired mutations...
  6. ncbi A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 294:245-53. 2010
    ..Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM...
  7. ncbi Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor
    Rina Nagao
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Lett 312:91-100. 2011
    ..The combination of AV65 with IM had a synergistic inhibitory effect on the proliferation of CML cells. These findings suggest that AV65 could be a novel therapeutic agent for the treatment of CML...
  8. ncbi Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan
    Oncol Res 15:1-9. 2005
    ..Ras does not appear to be the molecular target for ZOL-induced growth inhibition. Prevention of geranylgeranylation rather than farnesylation is an important therapeutic target in prostate cancer...
  9. ncbi Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Hematol 79:37-43. 2004
    ..Furthermore, one day of ZOL pretreatment augmented the sensitivity of imatinib and Ara-C. Therefore, concurrent or sequential administration of ZOL with imatinib, HU, Ara-C, or DNR may increase the efficacy of leukemia treatment...
  10. ncbi Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Blood 116:2089-95. 2010
    ..These data together support further clinical investigation of AT9283 in patients with imatinib- and second-generation ABL TKI-resistant BCR-ABL(+) cells, including T315I...
  11. ncbi NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Blood 106:3948-54. 2005
    ..NS-187 also inhibits Lyn without affecting the phosphorylation of Src, Blk, or Yes. These results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Philadelphia-positive (Ph+) leukemia...
  12. ncbi Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
    Yasuyuki Deguchi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 32:980-3. 2008
    ..Both nilotinib and INNO-406 were potent inhibitors of the dasatinib-resistant T315A, F317L and F317V BCR-ABL mutations...
  13. ncbi A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Clin Cancer Res 11:853-9. 2005
    ..Minodronic acid (YM529) is a third-generation nitrogen-containing bisphosphonate. Here, we have investigated the therapeutic efficacy of YM529 against renal cell cancer (RCC) alone or in combination with IFN both in vitro and in vivo...
  14. ncbi Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
    Kiyoshi Sato
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Cancer 116:94-9. 2005
    ..These findings show that ZOL significantly stimulated the proliferation of gammadeltaT cells and that gammadeltaT cells required pre-treatment with ZOL for cytotoxic activity against target cells...
  15. ncbi beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model
    Eishi Ashihara
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto University Hospital, Kyoto, Japan
    Clin Cancer Res 15:2731-8. 2009
    ..beta-catenin overexpression correlates positively with prognosis in several types of malignancies. We herein assessed its effects on growth of multiple myeloma cells using a xenograft model...
  16. ncbi Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    J Clin Invest 115:978-85. 2005
    ..We believe intravesical siRNA instillation against bladder cancer will be useful as a therapeutic tool...
  17. ncbi Osteoclasts are involved in the maintenance of dormant leukemic cells
    Asumi Yokota
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Leuk Res 34:793-9. 2010
    ..The results of our in vitro experiments suggest that OCs could be involved in the maintenance of dormant leukemic cells in the bone marrow (BM) microenvironment through the release of soluble factors, one of which could be TGF-beta...
  18. ncbi Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells
    Miki Takeuchi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Cancer Sci 102:591-6. 2011
    ..In conclusion, Rakicidin A is a promising compound for targeting TKI-resistant quiescent CML stem cells in the hypoxic BM environment...
  19. ncbi Intraoperative blood loss during living donor liver transplantation: an analysis of 635 recipients at a single center
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Transfusion 45:879-84. 2005
    ....
  20. ncbi Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis
    Kazuki Sakai
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Eur J Immunol 41:67-75. 2011
    ..In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD...
  21. ncbi Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
    Cancer Lett 217:243-53. 2005
    ..We believe the models we have established in combination with the in vivo imaging system will be highly useful for future studies of metastasis and the testing of anti-metastatic therapies...
  22. ncbi Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia
    Toshio Kitawaki
    Department of Hematology and Oncology, Kyoto University Hospital, Sakyo ku, Kyoto, Japan
    Exp Hematol 39:424-433.e2. 2011
    ..To explore the potential of immunotherapy for improving clinical outcomes for these patients, we performed a phase I clinical trial of dendritic cell (DC)-based immunotherapy for elderly patients with AML...
  23. ncbi p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan
    Cancer Sci 95:186-92. 2004
    ..ZOL also affected the coordinate expression patterns of several cell cycle regulators during the execution of anti-tumor activity...
  24. ncbi Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan
    Cancer Lett 312:228-34. 2011
    ..Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients...
  25. ncbi Effects of low-intensity pulsed ultrasound on osteosarcoma and cancer cells
    Yasushi Sawai
    Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, and Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kamigyo ku, Kyoto 602 8566, Japan
    Oncol Rep 28:481-6. 2012
    ..Our study suggests that LIPUS may be a new method of treatment without surgery for metastatic bone tumors...
  26. ncbi Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Int J Cancer 113:158-65. 2005
    ..Thus, a novel anti-cancer drug, GUT-70 isolated from the stem bark of C. brasiliense induces caspase-mediated and p53-independent apoptosis to overcome multidrug resistance and may become a potent leukemia therapeutics...
  27. ncbi Future prospect of RNA interference for cancer therapies
    Eishi Ashihara
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Shogoin Sakyo ku, Kyoto, 606 8507, Japan
    Curr Drug Targets 11:345-60. 2010
    ..Results of current studies and clinical trials demonstrate that manipulation of RNAi mechanism by use of targeted siRNA offers promising strategies for cancer therapies...
  28. ncbi Rapid quantitation of immunoglobulin G antibodies specific for blood group antigens A and B by surface plasmon resonance
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kawahara-cho Shogoin, Sakyo-ku, Kyoto, Japan
    Transfusion 45:56-62. 2005
    ..CONCLUSION: This SPR method can be used to measure IgG anti-A/B titers in the plasma very quickly and quantitatively...
  29. ncbi Fully automated and super-rapid system for the detection of JAK2V617F mutation
    Ruriko Tanaka
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Leuk Res 32:1462-7. 2008
    ..The presence of JAK2V617F mutation in these 7 specimens was confirmed by allele-specific PCR. These findings indicate that QP-system is more sensitive and useful than direct sequencing for diagnoses of CMPDs...
  30. ncbi [Overcoming imatinib resistance]
    Eishi Ashihara
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital
    Nippon Rinsho 65:399-403. 2007
  31. ncbi [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia]
    Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital
    Gan To Kagaku Ryoho 34:301-4. 2007
    ..Considerations important for the innovation of clinical trials for anti-cancer drugs in Japan are discussed...
  32. ncbi Cyclic AMP responsive element binding proteins are involved in 'emergency' granulopoiesis through the upregulation of CCAAT/enhancer binding protein β
    Hideyo Hirai
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    PLoS ONE 8:e54862. 2013
    ..These data suggest that CREB proteins are involved in the regulation of granulopoiesis via C/EBPβ upregulation...
  33. ncbi Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts
    Aya Miyagawa-Hayashino
    Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
    Liver Transpl 18:1333-42. 2012
    ....
  34. ncbi [Detection of antibodies specific for blood group antigens A and B]
    Kimiko Yurugi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507
    Rinsho Byori 53:1011-8. 2005
    ..Therefore, we have developed a method based on surface plasmon resonance (SPR) that detects the presence of the antigen-antibody complex without any labeling. This method allows us to rapidly quantitate anti-A/B IgG Ab levels...
  35. ncbi New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Shinya Kimura
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    Curr Pharm Biotechnol 7:371-9. 2006
    ..It may be necessary for the improvement of CML and Ph(+)ALL treatment to be taken into consideration of the combination therapy with novel ATP-competitive inhibitors and these agents...
  36. ncbi Significance of C4d staining in ABO-identical/compatible liver transplantation
    Hiromi Sakashita
    Laboratory of Diagnostic Pathology, Kyoto University Hospital, Sakyo ku, Kyoto, Japan
    Mod Pathol 20:676-84. 2007
    ....
  37. ncbi Human leukocyte antigens in Japanese patients with biliary atresia: retrospective analysis of patients who underwent living donor liver transplantation
    Takeshi Yuasa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    Hum Immunol 66:295-300. 2005
    ..We speculate that a gene at the locus close to HLA plays an important role in the pathogenesis of BA...
  38. ncbi Targeting the Wnt/β-catenin signaling pathway in human cancers
    Hisayuki Yao
    Kyoto University Hospital, Department of Transfusion Medicine and Cell Therapy, Kyoto, Japan
    Expert Opin Ther Targets 15:873-87. 2011
    ..Progress has been made in the development of screening methods to identify Wnt/β-catenin signaling inhibitors. Biomarker-based screening is an effective and promising method for the identification of compounds of interest...
  39. ncbi [Supportive therapies for myeloid leukemia including blood transfusion and growth factors]
    Hisayuki Yao
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital
    Nihon Rinsho 67:1951-7. 2009
    ..Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia...
  40. ncbi Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia
    Toshio Kitawaki
    Department of Hematology and Oncology, Kyoto University Hospital, Kyoto, Japan
    Am J Hematol 83:315-7. 2008
    ....
  41. ncbi In-hospital mortality in adult recipients of living donor liver transplantation: experience of 576 consecutive cases at a single center
    Toshimi Kaido
    Department of Hepato Biliary Pancreatic and Transplant Surgery, Kyoto University School of Medicine, Kyoto, Japan
    Liver Transpl 15:1420-5. 2009
    ..Enteral nutrition could be a promising strategy to improve adult LDLT...
  42. ncbi B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation
    Hiroto Egawa
    Department of Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
    Liver Transpl 13:579-88. 2007
    ....
  43. ncbi Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma
    Shinya Kimura
    Department of Transfusion Medicine, Kyoto University Hospital, Kyoto, Japan
    Blood 101:4219-21. 2003
    ....
  44. ncbi ABO-incompatible living-donor lobar lung transplantation
    Tsuyoshi Shoji
    Department of Thoracic Surgery, Kyoto University, 54 Shogoin Kawahara cho, Kyoto, Japan
    J Heart Lung Transplant 30:479-80. 2011
    ..To our knowledge, this case represents the first successful living-donor lobar lung transplantation from ABO-incompatible donors...
  45. ncbi Insulin independence after living-donor distal pancreatectomy and islet allotransplantation
    Shinichi Matsumoto
    Kyoto University Hospital Transplantation Unit, Kyoto Japan
    Lancet 365:1642-4. 2005
    ..The donor had no complications and both women showed healthy glucose tolerance. Transplantation of living-donor islets from the distal pancreas can be sufficient to reverse brittle diabetes...
  46. ncbi Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants: effect on survival
    Eishi Ashihara
    Department of Blood Transfusion and Cell Therapy, Kyoto, Japan
    Transplantation 83:506-9. 2007
    ..5%; negative group, 81.9%; P=3.3x10). We conclude that antidonor antibodies have adverse effects on the clinical outcome of LDLTs, and that being female and/or older aged (>or=18 years of age) are risk factors for LDLT...
  47. ncbi Successful islet transplantation from nonheartbeating donor pancreata using modified Ricordi islet isolation method
    Shinichi Matsumoto
    Kyoto University Hospital Transplantation Unit, Kyoto, Japan
    Transplantation 82:460-5. 2006
    ..The goal of this study was to improve the efficacy of islet transplantation using nonheartbeating donors (NHBDs)...
  48. ncbi C/EBPβ Is Involved in the Amplification of Early Granulocyte Precursors during Candidemia-Induced "Emergency" Granulopoiesis
    Sakiko Satake
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606 8507, Japan
    J Immunol 189:4546-55. 2012
    ..Taken together, these data suggest that C/EBPβ is involved in the efficient amplification of early granulocyte precursors during candidemia-induced emergency granulopoiesis...
  49. ncbi Use of bicistronic vectors in combination with flow cytometry to screen for effective small interfering RNA target sequences
    Naoka Kamio
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Biochem Biophys Res Commun 393:498-503. 2010
    ..Because of its simplicity and effectiveness, this method will facilitate the screening of effective siRNA target sequences, even in high-throughput applications...
  50. ncbi RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers
    Eri Kawata
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    J Clin Bioinforma 1:6. 2011
    ..PLK-1 regulates the mitotic process in mammalian cells. These promising results demonstrate that PLK-1 is a suitable target for advanced NSCLC therapy...
  51. ncbi The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate
    Junya Kuroda
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    Blood 102:2229-35. 2003
    ..These findings indicate that ZOL is a potent antileukemic agent that augments synergistically the anti-Ph+ leukemia activity of imatinib mesylate...
  52. ncbi Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia
    Seiichiro Katagiri
    First Department of Internal Medicine, Tokyo Medical University, Shinjuku ku, Tokyo, Japan
    Clin Cancer Res 19:1422-32. 2013
    ..The clear link between the Hedgehog pathway and BCR-ABL1-positive leukemia led to an effort to identify small molecules to block the pathway...
  53. ncbi [Education of laboratory technicians at graduate school contributes to development of advanced medical sciences and therapeutics]
    Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Center for Cell and Molecular Therapy, Kyoto University Hospital, Kyoto 606-8507
    Rinsho Byori 52:430-4. 2004
    ..Such technicians should be educated at a graduate school of medicine for health science. GMP-cell processing is an active field for such graduates...
  54. ncbi Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification
    Koji Morinaga
    Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
    Int J Cancer 122:2621-7. 2008
    ..Because BCR-ABL gene amplification occurs in blast crisis, these inhibitors might overcome IM resistance in such patients' leukemia...
  55. ncbi ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms
    Junya Kuroda
    Division of Haematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kamigyo ku, Kyoto, Japan
    Br J Haematol 140:181-90. 2008
    ..These results suggest that ABT-737 is a useful component of chemotherapies for CML with diverse drug-resistance mechanisms...
  56. ncbi Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
    Seiji Matsumoto
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan
    Lung Cancer 47:31-9. 2005
    ..These findings indicate that ZOL and combined use of these agents may be promising therapeutic strategies for SCLC...
  57. ncbi Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings
    Kenzaburo Tani
    Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Mol Ther 10:799-816. 2004
    ..Our results suggest that GVAX substantially enhanced the antitumor cellular and humoral immune responses, which might have contributed to the relatively long survival times of our patients in the present study...
  58. ncbi Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin
    Junya Kuroda
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kamigyo ku, Kyoto 602 8566, Japan
    Int J Hematol 87:507-15. 2008
    ..These results suggest that HHT could constitute an attractive option for MM treatment though its ability to simultaneously target multiple tumor-promoting molecules...
  59. ncbi The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis
    Naoyuki Horie
    Department of Orthopaedics, Graduate School of Medical Science Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji, Kyoto, 602 8566, Japan
    Cancer Lett 238:111-8. 2006
    ..These observations suggest that third-generation BPs directly affect on the proliferation and survival of osteosarcoma cells, which supports the possibility that they could be beneficial in the treatment of osteosarcoma patients...
  60. ncbi Zoledronic acid - a multiplicity of anti-cancer action
    Takeshi Yuasa
    Department of Urology, Akita University School of Medicine, 1 1 1 Hondo, Akita, Japan
    Curr Med Chem 14:2126-35. 2007
    ..The accumulated encouraging evidence to date indicate that ZOL is an attractive anti-cancer agent which promises to be the next exciting therapy for patients with various cancers...
  61. ncbi [Targeting Ras related proteins for leukemia therapy]
    Shinya Kimura
    Rinsho Ketsueki 46:179-86. 2005
  62. ncbi In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations
    Haruna Naito
    Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, 14 Nishinosho Mongucgi-Cho, Minami-ku, Kyoto 601-8550, Japan
    Leuk Res 30:1443-6. 2006
    ..Furthermore, NS-187 prolonged the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl tested except T315I, and its efficacy correlated well with its in vitro effects...
  63. ncbi siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis
    Makoto Wada
    Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kawaramachi Hirokoji, Kamigyo ku, Kyoto 602 8566, Japan
    Biochem Biophys Res Commun 357:353-9. 2007
    ..These findings suggest that PLK-1 plays a critical role in the proliferation of RA synoviocytes leading to bone destruction, and siRNA against PLK-1 is potentially useful for the treatment of RA...
  64. ncbi [Delayed hemolytic transfusion reaction (DHTR)--unrecognized and underestimated clinico-pathological conditions]
    Taira Maekawa
    Rinsho Ketsueki 49:1306-14. 2008
  65. ncbi Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
    Hitomi Nagayama
    Division of Cell Processing, Department of Advanced Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Melanoma Res 13:521-30. 2003
    ....
  66. ncbi [Establishment of institutional GMP cell processing is mandatory for the development of novel advanced cell and gene therapy]
    Taira Maekawa
    Rinsho Ketsueki 45:32-8. 2004
  67. ncbi Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease
    Kazuho Shimura
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Biol Blood Marrow Transplant 14:426-37. 2008
    ..In conclusion, s-cGVHD patients show findings consistent with those seen in PSS with impaired vasculogenesis that may limit blood perfusion and may contribute to the development of sclerodermatous lesions...
  68. ncbi Real-time monitoring of antibody secretion from B-cells on a microchip stimulated with a minute amount of mitogen
    Tatsuya Munaka
    Technology Research Laboratory, Shimadzu Corporation, 3 9 4 Hikari dai, Seika cho, Soraku gun, Kyoto 619 0237, Japan
    Analyst 132:512-4. 2007
    ....
  69. ncbi Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface
    Ryo Uchida
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Biochem Biophys Res Commun 354:613-8. 2007
    ..In conclusion, gammadeltaT cells recognize the mevalonate metabolites and ICAM-1 on myeloma cells...